United States · Biotechnology startup
United States · Caribou Biosciences
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Funding reportedLast round: Post-IPO Equity
What company datasets say Caribou Biosciences raised
Funding, as reported
Reported in all$125Min dollars
Last roundPost-IPO Equity
Investors listed5
SEC Form D$144M sold, 4 filings, last Mar 2021
Founders and team
From Caribou Biosciences's own website and the SEC filings it signed: 7 on the team.
- Reigin ZawadzkiChief people officer
- Sri RyaliChief financial officer
- Andrew GuggenhimeBoard of directors
- Barbara G. McClungExecutive Officeri
- Jason B. O'ByrneExecutive Officeri
- Rachel E. HaurwitzExecutive Officer, Directori
- Steven B. KannerExecutive Officeri
On the board, as filediJeffrey G. Long-McGieNatalie R. SacksRobert E. WeisskoffSanthosh G. Palani
On 5 portfolio pages
Investors who name them
Each firm lists Caribou Biosciences on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Caribou Biosciences in front of investors. Or tell us what we have wrong.